Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling

Yan G. Ni, Kambeez Berenji, Na Wang, Misook Oh, Nita Sachan, Asim Dey, Jun Cheng, Guangrong Lu, David J. Morris, Diego H Castrillon, Robert D. Gerard, Beverly A Rothermel, Joseph A Hill

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

BACKGROUND - Cellular hypertrophy requires coordinated regulation of progrowth and antigrowth mechanisms. In cultured neonatal cardiomyocytes, Foxo transcription factors trigger an atrophy-related gene program that counters hypertrophic growth. However, downstream molecular events are not yet well defined. METHODS AND RESULTS - Here, we report that expression of either Foxo1 or Foxo3 in cardiomyocytes attenuates calcineurin phosphatase activity and inhibits agonist-induced hypertrophic growth. Consistent with these results, Foxo proteins decrease calcineurin phosphatase activity and repress both basal and hypertrophic agonist-induced expression of MCIP1.4, a direct downstream target of the calcineurin/NFAT pathway. Furthermore, hearts from Foxo3-null mice exhibit increased MCIP1.4 abundance and a hypertrophic phenotype with normal systolic function at baseline. Together, these results suggest that Foxo proteins repress cardiac growth at least in part through inhibition of the calcineurin/NFAT pathway. Given that hypertrophic growth of the heart occurs in multiple contexts, our findings also suggest that certain hypertrophic signals are capable of overriding the antigrowth program induced by Foxo. Consistent with this, multiple hypertrophic agonists triggered inactivation of Foxo proteins in cardiomyocytes through a mechanism requiring the PI3K/Akt pathway. In addition, both Foxo1 and Foxo3 are phosphorylated and consequently inactivated in hearts undergoing hypertrophic growth induced by hemodynamic stress. CONCLUSIONS - This study suggests that inhibition of the calcineurin/NFAT signaling cascade by Foxo and release of this repressive action by the PI3K/Akt pathway are important mechanisms whereby Foxo factors govern cell growth in the heart.

Original languageEnglish (US)
Pages (from-to)1159-1168
Number of pages10
JournalCirculation
Volume114
Issue number11
DOIs
StatePublished - Sep 2006

Fingerprint

Calcineurin
Cardiomegaly
Transcription Factors
Growth
Cardiac Myocytes
Phosphatidylinositol 3-Kinases
Proteins
Hypertrophy
Atrophy
Hemodynamics
Phenotype
Genes

Keywords

  • Angiotensin
  • Calcineurin
  • Hypertrophy

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. / Ni, Yan G.; Berenji, Kambeez; Wang, Na; Oh, Misook; Sachan, Nita; Dey, Asim; Cheng, Jun; Lu, Guangrong; Morris, David J.; Castrillon, Diego H; Gerard, Robert D.; Rothermel, Beverly A; Hill, Joseph A.

In: Circulation, Vol. 114, No. 11, 09.2006, p. 1159-1168.

Research output: Contribution to journalArticle

Ni, YG, Berenji, K, Wang, N, Oh, M, Sachan, N, Dey, A, Cheng, J, Lu, G, Morris, DJ, Castrillon, DH, Gerard, RD, Rothermel, BA & Hill, JA 2006, 'Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling', Circulation, vol. 114, no. 11, pp. 1159-1168. https://doi.org/10.1161/CIRCULATIONAHA.106.637124
Ni, Yan G. ; Berenji, Kambeez ; Wang, Na ; Oh, Misook ; Sachan, Nita ; Dey, Asim ; Cheng, Jun ; Lu, Guangrong ; Morris, David J. ; Castrillon, Diego H ; Gerard, Robert D. ; Rothermel, Beverly A ; Hill, Joseph A. / Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. In: Circulation. 2006 ; Vol. 114, No. 11. pp. 1159-1168.
@article{57780fcacb4947d6aed56614b63796c2,
title = "Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling",
abstract = "BACKGROUND - Cellular hypertrophy requires coordinated regulation of progrowth and antigrowth mechanisms. In cultured neonatal cardiomyocytes, Foxo transcription factors trigger an atrophy-related gene program that counters hypertrophic growth. However, downstream molecular events are not yet well defined. METHODS AND RESULTS - Here, we report that expression of either Foxo1 or Foxo3 in cardiomyocytes attenuates calcineurin phosphatase activity and inhibits agonist-induced hypertrophic growth. Consistent with these results, Foxo proteins decrease calcineurin phosphatase activity and repress both basal and hypertrophic agonist-induced expression of MCIP1.4, a direct downstream target of the calcineurin/NFAT pathway. Furthermore, hearts from Foxo3-null mice exhibit increased MCIP1.4 abundance and a hypertrophic phenotype with normal systolic function at baseline. Together, these results suggest that Foxo proteins repress cardiac growth at least in part through inhibition of the calcineurin/NFAT pathway. Given that hypertrophic growth of the heart occurs in multiple contexts, our findings also suggest that certain hypertrophic signals are capable of overriding the antigrowth program induced by Foxo. Consistent with this, multiple hypertrophic agonists triggered inactivation of Foxo proteins in cardiomyocytes through a mechanism requiring the PI3K/Akt pathway. In addition, both Foxo1 and Foxo3 are phosphorylated and consequently inactivated in hearts undergoing hypertrophic growth induced by hemodynamic stress. CONCLUSIONS - This study suggests that inhibition of the calcineurin/NFAT signaling cascade by Foxo and release of this repressive action by the PI3K/Akt pathway are important mechanisms whereby Foxo factors govern cell growth in the heart.",
keywords = "Angiotensin, Calcineurin, Hypertrophy",
author = "Ni, {Yan G.} and Kambeez Berenji and Na Wang and Misook Oh and Nita Sachan and Asim Dey and Jun Cheng and Guangrong Lu and Morris, {David J.} and Castrillon, {Diego H} and Gerard, {Robert D.} and Rothermel, {Beverly A} and Hill, {Joseph A}",
year = "2006",
month = "9",
doi = "10.1161/CIRCULATIONAHA.106.637124",
language = "English (US)",
volume = "114",
pages = "1159--1168",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling

AU - Ni, Yan G.

AU - Berenji, Kambeez

AU - Wang, Na

AU - Oh, Misook

AU - Sachan, Nita

AU - Dey, Asim

AU - Cheng, Jun

AU - Lu, Guangrong

AU - Morris, David J.

AU - Castrillon, Diego H

AU - Gerard, Robert D.

AU - Rothermel, Beverly A

AU - Hill, Joseph A

PY - 2006/9

Y1 - 2006/9

N2 - BACKGROUND - Cellular hypertrophy requires coordinated regulation of progrowth and antigrowth mechanisms. In cultured neonatal cardiomyocytes, Foxo transcription factors trigger an atrophy-related gene program that counters hypertrophic growth. However, downstream molecular events are not yet well defined. METHODS AND RESULTS - Here, we report that expression of either Foxo1 or Foxo3 in cardiomyocytes attenuates calcineurin phosphatase activity and inhibits agonist-induced hypertrophic growth. Consistent with these results, Foxo proteins decrease calcineurin phosphatase activity and repress both basal and hypertrophic agonist-induced expression of MCIP1.4, a direct downstream target of the calcineurin/NFAT pathway. Furthermore, hearts from Foxo3-null mice exhibit increased MCIP1.4 abundance and a hypertrophic phenotype with normal systolic function at baseline. Together, these results suggest that Foxo proteins repress cardiac growth at least in part through inhibition of the calcineurin/NFAT pathway. Given that hypertrophic growth of the heart occurs in multiple contexts, our findings also suggest that certain hypertrophic signals are capable of overriding the antigrowth program induced by Foxo. Consistent with this, multiple hypertrophic agonists triggered inactivation of Foxo proteins in cardiomyocytes through a mechanism requiring the PI3K/Akt pathway. In addition, both Foxo1 and Foxo3 are phosphorylated and consequently inactivated in hearts undergoing hypertrophic growth induced by hemodynamic stress. CONCLUSIONS - This study suggests that inhibition of the calcineurin/NFAT signaling cascade by Foxo and release of this repressive action by the PI3K/Akt pathway are important mechanisms whereby Foxo factors govern cell growth in the heart.

AB - BACKGROUND - Cellular hypertrophy requires coordinated regulation of progrowth and antigrowth mechanisms. In cultured neonatal cardiomyocytes, Foxo transcription factors trigger an atrophy-related gene program that counters hypertrophic growth. However, downstream molecular events are not yet well defined. METHODS AND RESULTS - Here, we report that expression of either Foxo1 or Foxo3 in cardiomyocytes attenuates calcineurin phosphatase activity and inhibits agonist-induced hypertrophic growth. Consistent with these results, Foxo proteins decrease calcineurin phosphatase activity and repress both basal and hypertrophic agonist-induced expression of MCIP1.4, a direct downstream target of the calcineurin/NFAT pathway. Furthermore, hearts from Foxo3-null mice exhibit increased MCIP1.4 abundance and a hypertrophic phenotype with normal systolic function at baseline. Together, these results suggest that Foxo proteins repress cardiac growth at least in part through inhibition of the calcineurin/NFAT pathway. Given that hypertrophic growth of the heart occurs in multiple contexts, our findings also suggest that certain hypertrophic signals are capable of overriding the antigrowth program induced by Foxo. Consistent with this, multiple hypertrophic agonists triggered inactivation of Foxo proteins in cardiomyocytes through a mechanism requiring the PI3K/Akt pathway. In addition, both Foxo1 and Foxo3 are phosphorylated and consequently inactivated in hearts undergoing hypertrophic growth induced by hemodynamic stress. CONCLUSIONS - This study suggests that inhibition of the calcineurin/NFAT signaling cascade by Foxo and release of this repressive action by the PI3K/Akt pathway are important mechanisms whereby Foxo factors govern cell growth in the heart.

KW - Angiotensin

KW - Calcineurin

KW - Hypertrophy

UR - http://www.scopus.com/inward/record.url?scp=33748675304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748675304&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.106.637124

DO - 10.1161/CIRCULATIONAHA.106.637124

M3 - Article

VL - 114

SP - 1159

EP - 1168

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 11

ER -